Alterity Therapeutics has dosed the first patient in Australia in its Phase II clinical trial of ATH434 for the treatment of early-stage multiple system atrophy (MSA), a debilitating Parkinsonian disorder.

The placebo-controlled, randomised, double-blind study will evaluate the safety and pharmacokinetics properties of ATH434 in more than 60 adult subjects.

Patients will receive one of two ATH434 dose levels or placebo for 12 months and the efficacy endpoints obtained further enable in designing a definitive Phase III study.

The effect of ATH434 treatment on neuroimaging and protein biomarkers to demonstrate target engagement will also be assessed in the study along with clinical endpoints to demonstrate efficacy.

Drug activity is demonstrated using brain iron and aggregating α‑synuclein biomarkers, which are said to be important contributors to MSA pathology.

Motor activities in patients with MSA are also evaluated using wearable sensors.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Dr Stephen Tisch from St Vincent’s Hospital in Sydney is the principal investigator of the trial.

Alterity Therapeutics CEO David Stamler said: “The dosing of our first MSA participant in Australia is an important milestone as we are now enrolling in five countries around the world.

“The trial has been well received by physicians as we are using state-of-the-art methods to diagnose and track the disease.

“We are grateful to Dr Tisch and the team at St Vincent’s Hospital for their ongoing efforts to advance the development of ATH434.”

An estimated 15,000 individuals in the US have MSA.